You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

ID: GL-END-C50-35 aoû 2023
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
F.C. Wright, J. Lipa, T. Zhong, E. Piliotis, Z. Ghorab, P. Stotland, M. Lee , Diagnosis and Treatment of BIA-ALCL Guideline Development Group

Guideline Objective

The objectives of this guideline are to provide recommendations on diagnosing and treating Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). The recommendations are based on the National Comprehensive Cancer Network (NCCN) Version 2.2022 T-Cell Lymphomas Guideline on BIA-ALCL.

Patient Population

Patients with suspected or confirmed BIA-ALCL.

Intended Guideline Users

The guideline document will support providers in diagnosing and treating patients with BIA-ALCL.

pdf download Full Report (PDF) (372.89 Ko)